ClinicalTrials.gg
CompletedNCT00798577Updated Mar 31, 2010Results posted

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

A Phase 4 interventional study of Vigamox Ophthalmic Solution and BSS placebo in Bacterial Conjunctivitis, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2010-03-31.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Conjunctivitis, Bacterial with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Conjunctivitis, Bacterial · United States.

Enrollment
19th of 20
24 · median 413
Started
2008
with 1 other
Phase 4
3 of 20
none open now
Registered
10th of 20
by date
Lead sponsor
4 of 20
Alcon Research

Among the 20 studies in Conjunctivitis, Bacterial with a site in United States, this one is the 19th largest by enrollment, is one of 2 that started in 2008, is one of 3 in phase 4, and was the 10th registered.

Conjunctivitis, Bacterial

40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.

Browse Conjunctivitis, Bacterial studies →

Open to participants now

2 of the 20 studies in Conjunctivitis, Bacterial with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Conjunctivitis, Bacterial studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Conjunctivitis, Bacterial with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the initial antibiotic effects in the treatment of bacterial conjunctivitis symptoms in subjects one year of age and older.

03

Conditions studied

  • Bacterial Conjunctivitis

Keywords

  • Bacterial Conjunctivitis
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis in one or both eyes of bacterial conjunctivitis based on:

    • symptoms less than or equal to 24 hours prior to first visit
    • rating > or equal to 1 for bulbar conjunctival injection
    • must have a rating > 1 for conjunctival discharge / exudate in at least one eye (the same eye as bulbar conjunctival injection ) at Visit 1, and
  2. Must experience some matting in the affected eye(s).
  3. 1 year of age or older, of any race and either sex
  4. Able to understand and sign an that has been approved by an Institutional Review Board; or if the subject is a minor, the informed consent must be signed and understood by the subjects legally authorized representative (parent or guardian). Assent to participate should be obtained from subjects 6 years of age or older unless not allowed by local regulation.
  5. Must agree to comply with study visit schedule, photographs and other study requirements. If subject is a minor, the parent or guardian must agree to ensure compliance.

Exclusion criteria

Exclusion Criteria:

  1. Cannot have had bacterial conjunctivitis as reported by subject (or parent if subject is a minor) for > 24 hours.
  2. Any current lid disease on clinical examination.
  3. Known or suspected allergy or to fluoroquinolones.
  4. Suspected fungal, viral (e.g. Herpes simplex) or Acanthamoeba infection, based on clinical observation.
  5. Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study (e.g., hepatitis, acute or chronic renal insufficiency).
  6. Use of topical ocular medications during the study period.
  7. Antibiotics (systemic or topical) may not be used within 7 day of visit 1 or anytime after this visit for the duration of the study.
  8. Women of not using reliable means of .
  9. Women who are pregnant or lactating.
  10. Enrollment of more than one person per household at the same time.
  11. Enrollment of the investigator or his or her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
  12. Participation in any drug or device study within 30 days of entering this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Vigamox

    Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)

    Drug: Vigamox Ophthalmic Solution

  • Placebo comparator
    BSS Placebo

    Balanced Salt Solution

    Drug: BSS placebo

Interventions

  • Moxifloxacin 5mg/mL 3 times daily for 7 days

  • DrugBSS placebo

    Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days

06

What researchers measure

Primary outcomes

  1. Exploratory Outcomes From Digital Photography

    Photographs were taken before and after treatment. Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.

    Time frame: 24 hours after administration of first dose

Secondary outcomes

  1. Exploratory Evaluation of Changes in Ocular Signs and Symptoms

    Number of patients who had clinical resolution (0 on all scales below) from baseline (Day 1) to Day 2 in ocular and symptoms of bacterial conjunctivitis: Bulbar Conjunctival Injection - 0 (none) to 4 (Severe) scale. Conjunctival Discharge (Mucopurulent) - 0 (none) to 3 (Severe) scale. Lid Erythema - 0 (none) to 3 (Severe) scale. Lid Swelling - 0 (none) to 3 (Severe) scale. Palpebral Conjunctiva - 0 (none) to 3 (Severe) scale. Foreign Body Sensation - 0 (none) to 3 (Severe) scale. Tearing - 0 (none) to 3 (Severe) scale. Photophobia - 0 (none) to 3 (Severe) scale.

    Time frame: Baseline (Day 1) to Day 2

  2. Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans

    Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1

    Time frame: 24 hours after administration of first dose

  3. Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like

    Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1

    Time frame: 24 hour after administration of first dose

  4. Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae

    Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1

    Time frame: 24 hours after administration of first dose

07

Results

Posted Mar 31, 2010

Participant flow

Participant flow — Overall Study
MilestoneVigamoxPlacebo
Started177
Completed177
Not completed00

Outcome measures

PrimaryExploratory Outcomes From Digital Photography

Photographs were taken before and after treatment. Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.

Time frame:
24 hours after administration of first dose
Reported as:
Number · Participants
Exploratory Outcomes From Digital Photography
ParticipantsVigamoxPlacebo
Exploratory Outcomes From Digital Photography177
SecondaryExploratory Evaluation of Changes in Ocular Signs and Symptoms

Number of patients who had clinical resolution (0 on all scales below) from baseline (Day 1) to Day 2 in ocular and symptoms of bacterial conjunctivitis: Bulbar Conjunctival Injection - 0 (none) to 4 (Severe) scale. Conjunctival Discharge (Mucopurulent) - 0 (none) to 3 (Severe) scale. Lid Erythema - 0 (none) to 3 (Severe) scale. Lid Swelling - 0 (none) to 3 (Severe) scale. Palpebral Conjunctiva - 0 (none) to 3 (Severe) scale. Foreign Body Sensation - 0 (none) to 3 (Severe) scale. Tearing - 0 (none) to 3 (Severe) scale. Photophobia - 0 (none) to 3 (Severe) scale.

Time frame:
Baseline (Day 1) to Day 2
Reported as:
Number · Participants
Exploratory Evaluation of Changes in Ocular Signs and Symptoms
ParticipantsVigamoxPlacebo
Exploratory Evaluation of Changes in Ocular Signs and Symptoms177
SecondaryMicrobiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans

Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1

Time frame:
24 hours after administration of first dose
Reported as:
Number · Percent bacteria eradicated
Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans
Percent bacteria eradicatedVigamoxPlacebo
Enterobacter faecalis17100
Candida albicans750
SecondaryMicrobiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like

Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1

Time frame:
24 hour after administration of first dose
Reported as:
Number · Percent bacteria eradicated
Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like
Percent bacteria eradicatedVigamoxPlacebo
Eradication of all other isolates100—
Corynform-like0—
SecondaryMicrobiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae

Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1

Time frame:
24 hours after administration of first dose
Reported as:
Number · Percent bacteria eradicated
Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae
Percent bacteria eradicatedVigamoxPlacebo
Staphylococcus Aureus—0
Steptococcus Pneumoniae—50
Enterobacter Cloacae—67

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vigamox—0/17 (0%)0/17 (0%)
Placebo—0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VigamoxPlaceboTotal
<=18 years7714
Between 18 and 65 years10010
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)VigamoxPlaceboTotal
Female11516
Male628
08

Study locations

1 site
  • Contact Alcon Call Center For Trial Locations
    Fort Worth, Texas 76134, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2008
First posted
Nov 26, 2008
Start
Oct 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Mar 31, 2010
Last update
Mar 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00798577
Lead sponsor
Alcon Research
Collaborators
Topical Solutions Ltd.
First posted
Nov 26, 2008
Start date
Oct 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Mar 31, 2010
Last update
Mar 31, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion